Home Biotechnology Bristol-Myers Squibb Company
B

Bristol-Myers Squibb Company

Profile managed by Bizz Id
United States 500+ employees

Description

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and delivers medicines for serious diseases. It focuses on oncology, hematology, immunology and neuroscience.

Products

16 products
Abatacept

Brand: Orencia.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Abatacept: see suppliers →

Atigotatug

In combination with nivolumab. 1L extensive-stage small cell lung cancer. Phase 3.

Under development

Finished product (FDF)

Verified on 2026-10-21

Atigotatug: see suppliers →

Belatacept

Brand: Nulojix.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Belatacept: see suppliers →

CD19 TCE

CD19 T-cell engager. Autoimmune diseases. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

CD33-GSPT1 ADC

CD33-GSPT1 antibody-drug conjugate. Acute myeloid leukemia. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

Elotuzumab

Brand: Empliciti.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Elotuzumab: see suppliers →

Imzokitug

With Ono. With pumitamig in 1L NSCLC in Phase 2; solid tumors in Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

Imzokitug: see suppliers →

Ipilimumab

Brand: Yervoy.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Ipilimumab: see suppliers →

Iza-bren

With SystImmune. EGFR-mutated NSCLC in Phase 3; TNBC and urothelial cancer in Phase 2; solid tumors in Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

Iza-bren: see suppliers →

Luspatercept

Brand: Reblozyl (legacy Celgene product). 1L transfusion-dependent myelofibrosis-associated anemia in registration (US), with Merck.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Luspatercept: see suppliers →

Moponetug

Alzheimer's disease. Phase 2.

Under development

Finished product (FDF)

Verified on 2026-10-21

Moponetug: see suppliers →

Nivolumab

Brand: Opdivo. Adjuvant hepatocellular carcinoma in Phase 3 (with Ono).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Nivolumab: see suppliers →

Nivolumab (SC)

Brand: Opdivo Qvantig. Nivolumab and hyaluronidase. With Yervoy in 1L non-small cell lung cancer in Phase 2.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Nivolumab: see suppliers →

Nivolumab + Relatlimab

Brand: Opdualag. High-dose (HD) formulation in 1L non-small cell lung cancer (PD-L1 ≥1%) in Phase 3.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Nivolumab: see suppliers → · Relatlimab: see suppliers →

Obexelimab

With Zenas BioPharma. IgG4-related disease. Phase 3.

Under development

Finished product (FDF)

Verified on 2026-10-21

Obexelimab: see suppliers →

Pumitamig

BNT327/BMS-986545, with BioNTech. ES-SCLC, NSCLC, TNBC and MSS colorectal cancer in Phase 3; 2L NSCLC and gastric cancer in Phase 2; HCC and RCC in Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

Pumitamig: see suppliers →

Contact company

Register for free to see this company’s contact details and get in touch.

Register - Free